Eratrectinib clinical trials
How each study uses eratrectinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the eratrectinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
Who runs them
Industry 6 · Other 0
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test eratrectinib, phase 3 first.
- Dec 2026Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid TumorsPhase 3 · Jiangsu vcare pharmaceutical technology co., LTD
Studies
Open first, then newest update. How each study uses eratrectinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of VC004 Capsules for Pain in Bone MetastasesNot yet recruitingPhase 1Jiangsu vcare pharmaceutical technology co., LTDNCT07731685Written as VC004 low dose
- Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid TumorsRecruitingPhase 3Jiangsu vcare pharmaceutical technology co., LTDNCT06658353Written as VC004 Capsules
- A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult SubjectsCompletedPhase 1Jiangsu vcare pharmaceutical technology co., LTDNCT06619951Written as VC004 and Itraconazole
- Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult SubjectsCompletedPhase 1Jiangsu vcare pharmaceutical technology co., LTDNCT06529445Written as High Dose VC004 Capsules
- The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid TumorsStatus unknownPhase 1/2Jiangsu vcare pharmaceutical technology co., LTDNCT04614740Written as VC004
- Food Effect Study on the Pharmacokinetics of VC004 Capsules in Healthy Adult SubjectsCompletedPhase 1Jiangsu vcare pharmaceutical technology co., LTDNCT05528120Written as VC004 Capsules
Codes
What other systems call eratrectinib · ClinicalTrials.gg INT018155
- UNII (FDA) UP4C2TYD49ERATRECTINIBConfirmed FDA, Wikidata
- Wikidata Q140529164eratrectinibConfirmed FDA, Wikidata
- NCI Thesaurus C178578EratrectinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | UP4C2TYD49 | ERATRECTINIB | Confirmed FDA, Wikidata |
| Wikidata | Q140529164 | eratrectinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C178578 | Eratrectinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.